BMS lung drug meets low-dose endpoint in Phase 3 but high dose fails to improve lung function

Bristol Myers Squibb reported that its LPA1 antagonist admilparant achieved the primary endpoint in a Phase 3 idiopathic pulmonary fibrosis study at the 60‑mg dose, showing a statistically significant improvement in forced vital capacity over placebo at week 52.

The higher 120‑mg dose did not reach statistical significance on the same measure, and the company did not disclose the underlying data for either dose.

Analysts described the results as mixed. Some view the low‑dose success as sufficient to support regulatory approval, while others point to the lack of a clear dose‑response relationship as a concern.

One analyst projected potential sales of $1.3 billion by 2032, reflecting optimism despite remaining questions about the drug’s overall efficacy profile.